Hearts & Minds Blog

Setting the Record Straight: The Facts About Bempedoic Acid

Tim Mayleben

President and Chief Executive Officer

We recently became aware of comments published containing misinterpretations or intentionally inaccurate statements regarding Esperion and bempedoic acid.  As the… more

ACC Scientific Session Reflections: A Conversation Among Members of The Lipid Management Team

Tim Mayleben

President and Chief Executive Officer

Mary McGowan

Chief Medical Officer

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

Last week The Lipid Management team attended the American College of Cardiology (ACC) 66th Annual Scientific Session in Washington D.C…. more

Validating Our Approach: Dr. Ference to Present Results from Mendelian Randomization Studies of ACL Inhibition at the Upcoming ACC Scientific Session

Tim Mayleben

President and Chief Executive Officer

As a team of lipid management experts, we often “geek out” on the science behind LDL-cholesterol lowering therapies. That’s why… more

Resilient and Relentlessly Focused in 2017

Tim Mayleben

President and Chief Executive Officer

Happy New Year! We welcomed 2017 with tremendous momentum as we advanced our bempedoic acid (ETC-1002) pivotal Phase 3 LDL… more

The History of LDL-Cholesterol with Dr. Antonio Gotto

Tim Mayleben

President and Chief Executive Officer

Antonio M. Gotto, Jr., MD, DPhil

Dean Emeritus and Co-Chair of Board of Overseers, Weill Cornell Medical College

As you know, Esperion is focused on developing and commercializing therapies for the treatment of patients with hypercholesterolemia who are… more